A, baseline and 4-week PET scan from patient 2 (MET c

Slides:

Advertisements

Similar presentations

Imaging Lab Key. #1 Xray Leg Fractured Shin Bone (Tibia)

Advertisements

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Bertram et al. (2005) , NEJM, 352: Bertram et al. (2005) , NEJM, 352:

MET Mutation Associated with Responsiveness to Crizotinib

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

MET-Mutated NSCLC with Major Response to Crizotinib

Figure 6 Image sequence demonstrating coronal cuts on MRI

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Alexa B. Schrock, PhD, Garrett M

Representative CT and PET/CT images of three patients with NSCLCs

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged.

CT Characteristics and Pathologic Basis of Solitary Cystic Lung Cancer

Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement Denis Maillet, MD, Isabelle Martel-Lafay,

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.

Pharmacologic inhibitors of PI3Kγ suppress PDAC growth and metastasis.

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

Correlation of changes in NAFCIST and PERCIST with cumulative activity with radium RaCl2 dose was negatively correlated with changes in NAFCIST.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Representative CT and PET/CT images of three patients with NSCLCs

IDO deficiency delays the development of pulmonary metastases.

A, Proportion of variants detected in the MMR genes.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Serial imaging before and after immunotherapy among patients.

Gamma camera images at 72 h of patient with T3N0M0 squamous cell cancer of the tongue base (patient 14). Gamma camera images at 72 h of patient with T3N0M0.

GM-CSF is required for CA-MSC–induced tumor metastasis.

Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer.

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

Serial chest CT scans of 33-year-old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and subsequent acquired resistance.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

Representative images demonstrating LOH in breast cancer patients’ paired BM aspirate and primary tumors (T) at D14S62, D14S51, and D8S321, respectively.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.

Change in FES uptake in the tumor during fulvestrant treatment.

Combined inhibition of coamplified RTKs is required for response.

Frequent coamplification of RTKs in MET-amplified EGC

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Representative patient responses to ulixertinib.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

A, VEGFR2 staining in the tumor rim and center.

Rapid autopsy reveals interlesional and intralesional heterogeneity of resistance. Rapid autopsy reveals interlesional and intralesional heterogeneity.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Representative biodistribution pattern of 111In-CMD-193.

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

Serial CT scan images from patient with a partial response.

Detection of E-cadherin fragments in human prostate cancer metastases.

Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.

BRAF in-frame deletion confers response to MAPK inhibition.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

BV6 increases bone metastasis.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

A, baseline and 4-week PET scan from patient 2 (MET c A, baseline and 4-week PET scan from patient 2 (MET c.3028G>C exon 14 splice variant) following treatment with cabozantinib. A, baseline and 4-week PET scan from patient 2 (MET c.3028G>C exon 14 splice variant) following treatment with cabozantinib. Imaging shows complete PET response by PERCIST criteria in the patient's liver metastasis. B, baseline and 4-week CT scan from patient 4 (MET c.3024_3028delAGAAGGTATATT exon 14 splice variant) following treatment with crizotinib. Imaging shows a response in the patient's lung tumor. C, baseline and 6-week CT scan from patient 5 (MET c.3028+1G>T exon 14 splice variant) following treatment with crizotinib. Imaging shows a response in the patient's lung tumor. D, baseline and 6-week CT scan from patient 5 (MET c.3028+1G>T exon 14 splice variant) following treatment with crizotinib. Imaging shows a response in the patient's liver metastasis. E, baseline and 8-week CT scan from patient 7 (MET c.3028G>T exon 14 splice variant) following treatment with crizotinib. Image shows a response in the patient's lung tumors. Paul K. Paik et al. Cancer Discov 2015;5:842-849 ©2015 by American Association for Cancer Research